Trial Profile

A Phase 1/2, Dose-Escalation and Cohort-Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of LAT010 in Patients with Advanced Solid Tumors (LIGHTSPEED-1)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 21 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LAT 010 (Primary)
Indications Adenocarcinoma; Breast cancer; Carcinoma; Colorectal cancer; Gastric cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms LIGHTSPEED-1
Sponsors Latticon Antibody Therapeutics

05 Jun 2024 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 May 2024 to 1 Jun 2024.
05 Jun 2024 Status changed from not yet recruiting to recruiting.
07 May 2024 Planned initiation date changed from 1 Mar 2024 to 1 May 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com